BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020;9. [PMID: 32047622 DOI: 10.12688/f1000research.20928.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Xu J, Xue P, Liu J, Luo L, Zhuge D, Yao Q, Li X, Zhao Y, Xu H. Thermo-sensitive hydrogel with mussel-inspired adhesion enhanced the non-fibrotic repair effect of EGF on colonic mucosa barrier of TNBS-induced ulcerative colitis rats through macrophage polarizing. Chemical Engineering Journal 2021;416:129221. [DOI: 10.1016/j.cej.2021.129221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Santos MLC, de Brito BB, da Silva FAF, Sampaio MM, Marques HS, Oliveira e Silva N, de Magalhães Queiroz DM, de Melo FF. Helicobacter pylori infection: Beyond gastric manifestations. World J Gastroenterol 2020; 26(28): 4076-4093 [PMID: 32821071 DOI: 10.3748/wjg.v26.i28.4076] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021;14:17562848211059954. [PMID: 34917173 DOI: 10.1177/17562848211059954] [Reference Citation Analysis]
4 Erdmann A, Rehmann-sutter C, Bozzaro C. Clinicians’ and Researchers’ Views on Precision Medicine in Chronic Inflammation: Practices, Benefits and Challenges. JPM 2022;12:574. [DOI: 10.3390/jpm12040574] [Reference Citation Analysis]
5 Vatn SS, Lindstrøm JC, Moen AE, Brackmann S, Tannæs TM, Olbjørn C, Bergemalm D, Keita ÅV, Gomollon F, Detlie TE, Lüders T, Kalla R, Adams A, Satsangi J, Jahnsen J, Vatn MH, Halfvarson J, Ricanek P, Nilsen H. Mucosal Gene Transcript Signatures in Treatment Naïve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort. CEG 2022;Volume 15:5-25. [DOI: 10.2147/ceg.s343468] [Reference Citation Analysis]
6 Brooks-warburton J, Ashton J, Dhar A, Tham T, Allen PB, Hoque S, Lovat LB, Sebastian S. Artificial intelligence and inflammatory bowel disease: practicalities and future prospects. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-102003] [Reference Citation Analysis]
7 Vatn S, Carstens A, Kristoffersen AB, Bergemalm D, Casén C, Moen AEF, Tannaes TM, Lindstrøm J, Detlie TE, Olbjørn C, Lindquist CM, Söderholm JD, Gomollón F, Kalla R, Satsangi J, Vatn MH, Jahnsen J, Halfvarson J, Ricanek P; IBD-Character Consortium. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character). Scand J Gastroenterol 2020;55:1146-56. [PMID: 32780604 DOI: 10.1080/00365521.2020.1803396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Thomas JP, Modos D, Korcsmaros T, Brooks-Warburton J. Network Biology Approaches to Achieve Precision Medicine in Inflammatory Bowel Disease. Front Genet 2021;12:760501. [PMID: 34745229 DOI: 10.3389/fgene.2021.760501] [Reference Citation Analysis]
9 Knyazev E, Maltseva D, Raygorodskaya M, Shkurnikov M. HIF-Dependent NFATC1 Activation Upregulates ITGA5 and PLAUR in Intestinal Epithelium in Inflammatory Bowel Disease. Front Genet 2021;12:791640. [PMID: 34858489 DOI: 10.3389/fgene.2021.791640] [Reference Citation Analysis]
10 Indellicato R, Trinchera M. Epigenetic Regulation of Glycosylation in Cancer and Other Diseases. Int J Mol Sci 2021;22:2980. [PMID: 33804149 DOI: 10.3390/ijms22062980] [Reference Citation Analysis]
11 Bqain M, Efimov A, Baker D, Kang AS. Immunogenicity of biologics used in the treatment of inflammatory bowel disease: A review. Hum Antibodies 2021. [PMID: 34151784 DOI: 10.3233/HAB-210449] [Reference Citation Analysis]
12 Wark G, Samocha-Bonet D, Ghaly S, Danta M. The Role of Diet in the Pathogenesis and Management of Inflammatory Bowel Disease: A Review. Nutrients 2020;13:E135. [PMID: 33396537 DOI: 10.3390/nu13010135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Bajaj J, Brenner D, Cai Q, Cash B, Crowell M, Dibaise J, Gallegos-orozco J, Gardner T, Gyawali C, Ha C, Holtmann G, Jamil L, Kaplan G, Karsan H, Kinoshita Y, Lebwohl B, Leontiadis G, Lichtenstein G, Longstreth G, Muthusamy V, Oxentenko A, Pimentel M, Pisegna J, Rubenstein J, Russo M, Saini S, Samadder N, Shaukat A, Simren M, Stevens T, Valdovinos M, Vargas H, Spiegel B, Lacy B. Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. Am J Gastroenterol 2020;115:1007-18. [DOI: 10.14309/ajg.0000000000000709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Genova E, Stocco G, Decorti G. Induced pluripotent stem cells to model adverse drug reactions in pediatric patients. Pharmacogenomics 2020;21:975-8. [PMID: 32893744 DOI: 10.2217/pgs-2020-0082] [Reference Citation Analysis]
15 Gomollón F, Louis E. Editorial: Personalizing Treatment in IBD: Hype or Reality in 2020? Front Med (Lausanne) 2021;8:673991. [PMID: 34026799 DOI: 10.3389/fmed.2021.673991] [Reference Citation Analysis]
16 Štambuk T, Klasić M, Zoldoš V, Lauc G. N-glycans as functional effectors of genetic and epigenetic disease risk. Mol Aspects Med 2021;79:100891. [PMID: 32861467 DOI: 10.1016/j.mam.2020.100891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
17 Hübenthal M, Löscher BS, Erdmann J, Franke A, Gola D, König IR, Emmert H. Current Developments of Clinical Sequencing and the Clinical Utility of Polygenic Risk Scores in Inflammatory Diseases. Front Immunol 2020;11:577677. [PMID: 33633722 DOI: 10.3389/fimmu.2020.577677] [Reference Citation Analysis]
18 Lees CW, Deuring JJ, Chiorean M, Daperno M, Bonfanti G, Germino R, Brown PB, Modesto I, Edwards RA. Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies. Therap Adv Gastroenterol 2021;14:17562848211054710. [PMID: 35154388 DOI: 10.1177/17562848211054710] [Reference Citation Analysis]
19 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, Gasbarrini A, Armuzzi A. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol 2021;14:17562848211006669. [PMID: 33995579 DOI: 10.1177/17562848211006669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Kröner PT, Engels MM, Glicksberg BS, Johnson KW, Mzaik O, van Hooft JE, Wallace MB, El-Serag HB, Krittanawong C. Artificial intelligence in gastroenterology: A state-of-the-art review. World J Gastroenterol 2021; 27(40): 6794-6824 [PMID: 34790008 DOI: 10.3748/wjg.v27.i40.6794] [Reference Citation Analysis]